About Atea Pharmaceuticals, Inc.
https://ateapharma.comAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19.
CEO
Jean-Pierre Sommadossi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 82
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:9.12M
Value:$32.29M
BLACKROCK, INC.
Shares:8.46M
Value:$29.95M
BML CAPITAL MANAGEMENT, LLC
Shares:7.47M
Value:$26.46M
Summary
Showing Top 3 of 128
About Atea Pharmaceuticals, Inc.
https://ateapharma.comAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $45.57M ▲ | $-42.05M ▼ | 0% | $-0.53 ▼ | $-41.75M ▼ |
| Q2-2025 | $0 | $38.93M ▲ | $-37.16M ▼ | 0% | $-0.44 ▼ | $-41.32M ▼ |
| Q1-2025 | $0 | $35.6M ▼ | $-34.27M ▼ | 0% | $-0.4 | $-38.94M ▼ |
| Q4-2024 | $0 | $38.92M ▲ | $-33.54M ▼ | 0% | $-0.4 ▼ | $-33.21M ▼ |
| Q3-2024 | $0 | $17.28M | $-31.15M | 0% | $-0.37 | $-30.86M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $329.31M ▼ | $342.96M ▼ | $27.18M ▼ | $315.78M ▼ |
| Q2-2025 | $379.71M ▼ | $391.61M ▼ | $27.19M ▼ | $364.42M ▼ |
| Q1-2025 | $425.44M ▼ | $439.96M ▼ | $28.88M ▲ | $411.08M ▼ |
| Q4-2024 | $454.72M ▼ | $464.67M ▼ | $25.8M ▼ | $438.87M ▼ |
| Q3-2024 | $482.81M | $490.96M | $32.44M | $458.52M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-42.05M ▼ | $-40.38M ▼ | $41.3M ▲ | $-11.3M ▲ | $-10.38M ▲ | $-40.38M ▼ |
| Q2-2025 | $-37.16M ▼ | $-32.87M ▼ | $15.29M ▼ | $-14.09M ▼ | $-31.67M ▼ | $-32.87M ▼ |
| Q1-2025 | $-34.27M ▼ | $-30.56M ▼ | $85.61M ▲ | $-347K ▼ | $54.7M ▲ | $-30.56M ▼ |
| Q4-2024 | $-33.54M ▼ | $-30.4M ▼ | $-3.37M ▲ | $0 ▼ | $-33.77M ▲ | $-30.4M ▼ |
| Q3-2024 | $-31.15M | $-23.04M | $-122.01M | $117K | $-144.93M | $-23.04M |
CEO
Jean-Pierre Sommadossi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 82
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:9.12M
Value:$32.29M
BLACKROCK, INC.
Shares:8.46M
Value:$29.95M
BML CAPITAL MANAGEMENT, LLC
Shares:7.47M
Value:$26.46M
Summary
Showing Top 3 of 128